---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-315039"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:30:09.665276+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corbus posts Phase 1a data for CRB-913: weight loss signal, no serious AEs; Phase 1b started

## Summary
- Phase 1a SAD/MAD of oral CB1 inverse agonist CRB-913 (n=112) showed no serious AEs, no GI intolerability, no neuropsychiatric events except mild anxiety/irritability in obese cohort.
- In obese MAD cohort (150 mg QD), all 9 CRB-913-treated participants lost weight; mean placebo-adjusted 2.9% loss at Day 14 (range 1.3-4.3%).
- Initiated Phase 1b CANYON-1 (12-week, 240 obese non-diabetic participants, doses 20/40/60 mg); completion expected summer 2026.
- PK profile supports once-daily dosing; no suicidality, depression, or insomnia reported across all study cohorts.

## SEC filing metadata
- accession: 0001193125-25-315039
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312525315039/0001193125-25-315039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312525315039/crbp-20251211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-315039
- JSON: https://secwatch.observer/filing/0001193125-25-315039.json
- Plain text: https://secwatch.observer/filing/0001193125-25-315039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.